Skip to content

A Study on Personalised Blood Pressure Management for Elderly Hypertensive Patients Using the U734T Sphygmomanometer, Guided by Atrial Fibrillation Risk Stratification

A Study on Personalised Blood Pressure Management for Elderly Hypertensive Patients Using the U734T Sphygmomanometer, Guided by Atrial Fibrillation Risk Stratification

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123777
Enrollment
Unknown
Registered
2026-04-29
Start date
2024-04-30
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High risk of atrial fibrillation in patients with hypertension

Interventions

Digital Management Group:One Omron U734T upper-arm blood pressure monitor (with atrial fibrillation risk alert function) (U734T, OMRON Healthcare Co. Ltd, China) will be issued. Patients will be instr
Routine Management Group:A validated upper-arm electronic blood pressure monitor without atrial fibrillation alert functionality (HEM-7173, OMRON Healthcare Co. Ltd, China) will be issued. Patients

Sponsors

Sichuan Provincial Second Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 60 years old (according to WHO and most geriatric research standards); 2. Meet the above hypertension diagnostic criteria, and have a qualifying CHA2DS2-VASc score; 3. Conscious, with basic communication and comprehension abilities, able to read or understand the informed consent form with family assistance; 4. Voluntarily participate in this study and sign a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Clearly diagnosed with atrial fibrillation, atrial flutter, or other persistent arrhythmias requiring anticoagulation treatment; secondary hypertension; severe structural heart disease (such as severe valvular heart disease, hypertrophic obstructive cardiomyopathy); history of cardiac pacemaker or implantable cardioverter-defibrillator implantation; 2. Complicated with malignant tumors (excluding non-melanoma skin cancer) that are active or with an expected lifespan of <2 years; end-stage renal disease (estimated glomerular filtration rate eGFR <15 mL/min/1.73m^2 or receiving dialysis); severe liver dysfunction (Child-Pugh class C); myocardial infarction, unstable angina, or stroke occurring within the past 6 months; 3. Currently participating in other clinical trials that may interfere with the outcomes of this study; planning to leave the local area within the next 6 months and unable to complete follow-up.

Design outcomes

Primary

MeasureTime frame
Electrocardiogram (ECG) examination rate;Atrial fibrillation (AF) detection rate;Time to Target Blood Pressure (TTR);

Secondary

MeasureTime frame
24-hour mean systolic blood pressure (SBP);24-hour mean diastolic blood pressure (DBP);24-hour mean pulse pressure (PP);Hypertension and Atrial Fibrillation Prevention Knowledge Assessment;Chinese Version of the Medication Adherence and Dosage Questionnaire (ARMS-10);Quality of Life Scale (EQ-5D-5L);

Countries

China

Contacts

Public ContactSu Kai

Sichuan Provincial Second Hospital of Traditional Chinese Medicine

SCCdd865@sina.com+86 159 2889 8112

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026